Literature DB >> 31570516

Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis.

Mostafa R Mohamed1, Erika Ramsdale1, Kah Poh Loh1, Asad Arastu1, Huiwen Xu1,2, Spencer Obrecht1, Daniel Castillo3, Manvi Sharma4, Holly M Holmes5, Ginah Nightingale6, Katherine M Juba7,8, Supriya G Mohile1.   

Abstract

BACKGROUND: Polypharmacy (PP) and potentially inappropriate medications (PIM) are highly prevalent in older adults with cancer. This study systematically reviews the associations of PP and/or PIM with outcomes and, through a meta-analysis, obtains estimates of postoperative outcomes associated with PP in this population.
MATERIALS AND METHODS: We searched PubMed, Embase, Web of Science, and Cochrane Register of Clinical Trials using standardized terms for concepts of PP, PIM, and cancer. Eligible studies included cohort studies, cross-sectional studies, meta-analyses, and clinical trials which examined outcomes associated with PP and/or PIM and included older adults with cancer. A random effects model included studies in which definitions of PP were consistent to examine the association of PP with postoperative complications.
RESULTS: Forty-seven articles met the inclusion criteria. PP was defined as five or more medications in 57% of the studies. Commonly examined outcomes included chemotherapy toxicities, postoperative complications, functional decline, hospitalization, and overall survival. PP was associated with chemotherapy toxicities (4/9 studies), falls (3/3 studies), functional decline (3/3 studies), and overall survival (2/11 studies). A meta-analysis of four studies indicated an association between PP (≥5 medications) and postoperative complications (overall odds ratio, 1.3; 95% confidence interval [1.3-2.8]). PIM was associated with adverse outcomes in 3 of 11 studies.
CONCLUSION: PP is associated with postoperative complications, chemotherapy toxicities, and physical and functional decline. Only three studies showed an association between PIM and outcomes. However, because of inconsistent definitions, heterogeneous populations, and variable study designs, these associations should be further investigated in prospective studies. IMPLICATIONS FOR PRACTICE: Polypharmacy and potentially inappropriate medications (PIM) are prevalent in older adults with cancer. This systematic review summarizes the associations of polypharmacy and PIM with health outcomes in older patients with cancer. Polypharmacy and PIM have been associated with postoperative complications, frailty, falls, medication nonadherence, chemotherapy toxicity, and mortality. These findings emphasize the prognostic importance of careful medication review and identification of PIM by oncology teams. They also underscore the need to develop and test interventions to address polypharmacy and PIM in older patients with cancer, with the goal of improving outcomes in these patients. © AlphaMed Press 2019.

Entities:  

Keywords:  Geriatric oncology; Older adults with cancer; Outcomes; Polypharmacy; Potentially inappropriate medications

Mesh:

Year:  2019        PMID: 31570516      PMCID: PMC6964156          DOI: 10.1634/theoncologist.2019-0406

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  79 in total

1.  The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.

Authors:  Daniel Westreich; Sander Greenland
Journal:  Am J Epidemiol       Date:  2013-01-30       Impact factor: 4.897

2.  The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Authors:  Kathleen Elliot; Janet A Tooze; Rachel Geller; Bayard L Powell; Timothy S Pardee; Ellen Ritchie; LeAnne Kennedy; Kathryn E Callahan; Heidi D Klepin
Journal:  Leuk Res       Date:  2014-07-07       Impact factor: 3.156

3.  Cumulative deficit model of geriatric assessment to predict the postoperative outcomes of older patients with solid abdominal cancer.

Authors:  Jakub Kenig; Urszula Olszewska; Beata Zychiewicz; Marcin Barczynski; Maria Mituś-Kenig
Journal:  J Geriatr Oncol       Date:  2015-07-03       Impact factor: 3.599

4.  Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers.

Authors:  Erika Ramsdale; Tatyana Lemelman; Kah Poh Loh; Marie Flannery; Lee Kehoe; Teraisa Mullaney; Megan Wells; Nikesha Gilmore; Sandy Plumb; Supriya Mohile
Journal:  J Geriatr Oncol       Date:  2018-03-09       Impact factor: 3.599

5.  Recommendations to support deprescribing medications late in life.

Authors:  Adam Todd; Holly M Holmes
Journal:  Int J Clin Pharm       Date:  2015-10

6.  Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.

Authors:  M E Hamaker; C Seynaeve; A N M Wymenga; H van Tinteren; J W R Nortier; E Maartense; H de Graaf; F E de Jongh; J J Braun; M Los; J G Schrama; A E van Leeuwen-Stok; S M de Groot; C H Smorenburg
Journal:  Breast       Date:  2013-12-05       Impact factor: 4.380

7.  Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer.

Authors:  Meghan S Karuturi; Holly M Holmes; Xiudong Lei; Michael Johnson; Carlos H Barcenas; Scott B Cantor; Gary E Gallick; Robert C Bast; Sharon H Giordano
Journal:  J Geriatr Oncol       Date:  2019-02-19       Impact factor: 3.599

8.  Prevalence and factors associated with polypharmacy in older people with cancer.

Authors:  Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

9.  Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer.

Authors:  Jun Woo Park; Jong-Lyel Roh; Sang-Wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-07       Impact factor: 4.553

10.  Inappropriate drug use in elderly patients is associated with prolonged hospital stay and increased postoperative mortality after colorectal cancer surgery: a population-based study.

Authors:  K S Samuelsson; M Egenvall; I Klarin; J Lökk; U Gunnarsson
Journal:  Colorectal Dis       Date:  2016-02       Impact factor: 3.788

View more
  27 in total

1.  Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: a population-based study.

Authors:  Yewon Suh; Young-Mi Ah; Eunsook Lee; Ju-Yeun Lee
Journal:  Support Care Cancer       Date:  2020-10-10       Impact factor: 3.603

2.  Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?

Authors:  José Alberto Domínguez-Alonso; David Conde-Estévez; David Bosch; Maria Pi-Figueras; Ignacio Tusquets
Journal:  Clin Transl Oncol       Date:  2020-05-24       Impact factor: 3.405

3.  Polypharmacy and prescription medication use in a population-based sample of adolescent and young adult cancer survivors.

Authors:  Andrea C Betts; Caitlin C Murphy; L Aubree Shay; Bijal A Balasubramanian; Christine Markham; Marlyn Allicock
Journal:  J Cancer Surviv       Date:  2022-01-08       Impact factor: 4.442

Review 4.  Older adults with cancer and their caregivers - current landscape and future directions for clinical care.

Authors:  Sindhuja Kadambi; Kah Poh Loh; Richard Dunne; Allison Magnuson; Ronald Maggiore; Jason Zittel; Marie Flannery; Julia Inglis; Nikesha Gilmore; Mostafa Mohamed; Erika Ramsdale; Supriya Mohile
Journal:  Nat Rev Clin Oncol       Date:  2020-09-02       Impact factor: 66.675

5.  Polypharmacy and frailty in older adults evaluated at a multidisciplinary geriatric-thoracic clinic prior to surgery.

Authors:  Lisa Cooper; Aaron R Dezube; Luis E De León; Sam Fox; Carlos E Bravo-Iñiguez; Emanuele Mazzola; Jeffrey Tarascio; Kristin Cardin; Clark DuMontier; Michael T Jaklitsch; Laura N Frain
Journal:  J Geriatr Oncol       Date:  2021-08-06       Impact factor: 3.929

6.  Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy.

Authors:  Heidi D Klepin; Can-Lan Sun; David D Smith; Rawad Elias; Kelly M Trevino; Ashley Leak Bryant; Daneng Li; Christian Nelson; William P Tew; Supriya G Mohile; Ajeet Gajra; Cynthia Owusu; Cary Gross; Stuart M Lichtman; Vani V Katheria; Hyman B Muss; Andrew E Chapman; Harvey Jay Cohen; Arti Hurria; William Dale
Journal:  JCO Oncol Pract       Date:  2021-04-21

7.  Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer.

Authors:  Amber S Kleckner; Megan Wells; Lee A Kehoe; Nikesha J Gilmore; Huiwen Xu; Allison Magnuson; Richard F Dunne; Marielle Jensen-Battaglia; Mostafa R Mohamed; Mark A O'Rourke; Nicholas J Vogelzang; Elie G Dib; Luke J Peppone; Supriya G Mohile
Journal:  JCO Oncol Pract       Date:  2021-07-06

8.  Prevalence of Polypharmacy, Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A Systematic Review and Meta-Analysis.

Authors:  Akshaya S Bhagavathula; Kota Vidyasagar; Manik Chhabra; Muhammed Rashid; Rishabh Sharma; Deepak K Bandari; Daniela Fialova
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

9.  Exploring polypharmacy with artificial intelligence: data analysis protocol.

Authors:  Caroline Sirois; Richard Khoury; Audrey Durand; Pierre-Luc Deziel; Olga Bukhtiyarova; Yohann Chiu; Denis Talbot; Alexandre Bureau; Philippe Després; Christian Gagné; François Laviolette; Anne-Marie Savard; Jacques Corbeil; Thierry Badard; Sonia Jean; Marc Simard
Journal:  BMC Med Inform Decis Mak       Date:  2021-07-20       Impact factor: 2.796

Review 10.  Understanding Treatment Tolerability in Older Adults With Cancer.

Authors:  Marie A Flannery; Eva Culakova; Beverly E Canin; Luke Peppone; Erika Ramsdale; Supriya G Mohile
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.